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Abstract
Background: Lithium is a first-line treatment for bipolar disorder in all phases, also indicated as add-on drug for unipolar depression and suicide prevention. 
This study encompasses a broad critical review on the safety and tolerability of lithium for mood disorders. Methods: A computerized search for English written 
human studies was made in MEDLINE, using the keywords “lithium” and “mood disorders”, starting from July 1993 through July 2013 (n = 416). This initial 
search aimed to select clinical trials, prospective data, and controlled design studies of lithium treatment for mood disorders reporting adverse effects (n = 
36). The final selection yielded 91 studies. Results: The most common general side effects in patients on lithium treatment were thirst, frequent urination, dry 
mouth, weight gain, fatigue and cognitive complaints. Lithium users showed a high prevalence of hypothyroidism, hyperparathyroidism, and decrease in urinary 
concentration ability. Reduction of glomerular filtration rate in patients using lithium was also observed, but in a lesser extent. The evidence of teratogenicity 
associated with lithium use is not well established. Anti-inflammatory non-steroidal drugs, thiazide diuretics, angiotensin-converting enzyme inhibitors, and 
alprazolam may increase serum lithium and the consequent risk for intoxication. Discussion: Short-term lithium treatment is associated with mild side effects. 
Medium and long-term lithium treatment, however, might have effects on target organs which may be prevented by periodical monitoring. Overall, lithium is 
still a safe option for the treatment of mood disorders. 
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Resumo
Contexto: O lítio é um tratamento de primeira linha para o transtorno bipolar, em todas as fases, e também é indicado como terapia adjunta para a depressão 
unipolar e prevenção do suicídio. Este estudo abrange uma ampla revisão crítica sobre a segurança e a tolerabilidade do lítio para transtornos do humor. 
Métodos: Uma busca informatizada para estudos com humanos escritos em inglês foi feita no MEDLINE, usando as palavras-chave “lítio” e “transtornos de 
humor”, a partir de julho de 1993 a julho de 2013 (n = 416). Esta pesquisa inicial teve como objetivo selecionar ensaios clínicos, estudos prospectivos e estudos 
controlados com tratamento com lítio para transtornos de humor, relatando efeitos adversos (n = 36). A seleção final identificou 91 estudos. Resultados: Os 
efeitos colaterais mais comuns nos pacientes em tratamento com lítio foram sede, micção frequente, boca seca, ganho de peso, fadiga e queixas cognitivas. 
Usuários de lítio mostraram uma alta prevalência de hipotireoidismo, hiperparatireoidismo e diminuição da capacidade de concentração urinária. Também 
foi observada redução da taxa de filtração glomerular em pacientes utilizando lítio, mas em menor grau. A evidência de teratogenicidade associada com o 
uso de lítio não está bem estabelecida. Os medicamentos anti-inflamatórios não esteroides, diuréticos, inibidores da enzima de conversão da angiotensina e 
alprazolam podem aumentar o lítio sérico e o consequente risco de intoxicação. Conclusões: O tratamento de curto prazo com lítio está associado com efeitos 
colaterais leves. No entanto, tratamentos de médio a longo prazo com lítio podem ter efeitos sobre órgãos-alvo que podem ser prevenidos por acompanhamento 
periódico. Em geral, o lítio é ainda uma alternativa segura para o tratamento dos transtornos de humor.
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Introduction
Lithium represents an important therapeutic option in mood dis-
orders, since its first clinical study by Mogens Schou in 19541. After 
almost 70 years of medical research, lithium salts have been shown 
effective for the protection against mania and depression, especially in 
the acute and long-term management of bipolar disorder2, and reduc-
ing both suicide and mortality in mood disorders3,4. More recently, 
new biological properties of lithium have been discovered, consid-
ering the drug for a pharmacological option for neurodegenerative 
and spinal cord disorders such as Alzheimer’s disease5, amyotrophic 
lateral sclerosis6 and chronic spinal cord injuries7. 
Although most guidelines recommend the prescription of lithium 
as a first-line drug for the treatment of bipolar disorder8, but clini-
cians need to pay attention to its clinical safety profile. Lithium has 
as a narrow therapeutic window and the requirement for frequent 
lithium serum levels, as well as the evaluation of potentially disabling 
adverse effects (e.g. thirst, taste alteration, tremor, polyuria, weight 
gain), and the risk of teratogenicity, and the possibility of emergence 
of organic lesions (Table 1) with long-term use may limit its use-
fulness in some cases. In this context, renal dysfunction has been 
implicated as a major concern of physicians who prescribe lithium 
salts, due to their potential for developing renal impairment, even 
with heterogeneous and inconclusive available data and a prevalence 
for severe impairment of 1.2%8-11.
Few studies have addressed the safety and tolerability of lithium in 
the clinical practice. First, the design of a randomized controlled trial 
studies in long-term (several years) maintenance is extremely expen-
sive and with a high dropout rate. Also, lithium has alternatives to its 
prescription, although more costly, such as valproic acid and second-
generation antipsychotics. These medications have beneficial actions 
very similar to lithium in the treatment of patients with mood disorders.
http://dx.doi.org/10.1590/0101-60830000411914
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The aim of this study is to present a critical review on the safety 
and tolerability profiles of lithium treatment for patients with mood 
disorders.
Methods
This study encompasses a broad critical review on the safety and 
tolerability of lithium for mood disorders. A computerized search 
for English written human studies was made in MEDLINE, using 
the keywords ‘lithium’ and ‘mood disorders’, starting from July 1993 
through July 2013. This initial search yielded 416 publications. A 
manual search especially evaluated clinical trials, prospective data, 
and controlled design studies involving lithium treatment for mood 
disorders (n = 36). In this search, our review dedicated a special 
interest on the last 10 years of evidence from randomized, placebo-
controlled, double-blind and controlled trials reporting adverse ef-
fects. Other articles reporting safety and tolerability data not reported 
in prospective or controlled studies were selected, as well as review 
papers on this issue. A secondary complementary search over this 
data range was done specifically addressing the keywords “lithium” 
and “safety”, “lithium” and “tolerability”, “lithium” and “depression”, 
and “lithium” and “bipolar disorder”. Manual search from reference 
lists of the primary selected studies was also done. Three authors 
participated in the studies selection (I.A., R.T.S., and L.C.L.V.). We 
selected a total of 91 studies.
Results
General aspects of commonly reported adverse effects
Several symptomatic adverse effects are associated with the use 
of lithium, being the most common abdominal discomfort, diar-
rhea, tremor, polyuria, nocturia, weight gain, edema, and various 
forms of erythema12. Anorexia, nausea, vomiting, abdominal pain 
and diarrhea are particularly transient, occurring most often at the 
beginning of treatment13. From the overall of these symptoms, the 
most pronounced effects and with greater impact for the patients 
are thirst, frequent urination, dry mouth, weight gain, fatigue and 
cognitive disorders14. Some forms of rash may occur during therapy 
with lithium and it may exacerbate previously diagnosed psoriasis. In 
controlled trials, 15 to 20% of patients discontinue treatment because 
of adverse events and this percentage may rise in more naturalist 
conditions15,16. The prevalence of these adverse effects is higher than 
20% during the long-term treatment directly related to the frequency 
and amount of the lithium salt administered9. However, the adhesion 
can be improved by providing accurate information about the drug, 
constant therapeutic supervision and psychological support17. The 
slow release formulations are associated with fewer adverse symptoms 
in clinical practice as previously described, especially regarding to 
digestive symptoms. In this latter, substitution of lithium carbonate 
by lithium citrate can occasionally improve this kind of complaint18. 
Weight gain between 4 to 10 pounds is found in approximately 
30% of patients9,19. However, in some studies, a gain above 20 
pounds is not uncommon13. Generally, the weight increase appears 
to be related to lithium insulin-like properties in increasing cellular 
glucose uptake, increased thirst, direct stimulation of the hypotha-
lamic appetite center, and the induction of clinical hypothyroidism. 
Although, no studies have explored the direct effect of lithium among 
users compared with control patients to evaluate possible specific 
influence with respect to weight gain. An experimental study with 
rats receiving low lithium levels, it was observed an increased serum 
levels of urea, glucose, and lipid peroxidase and reduced glutathione 
levels, indicating oxidative stress20. In this study, the histopathological 
examination of the tissues of the liver and kidneys showed various 
structural deformities and histological changes in rats treated with 
lithium. One possibility is the elevation of glucose reflects a change 
in pancreatic metabolism due to insulin deficiency. However, in an-
other study with similar experimental design and histopathological 
findings, changes in glucose metabolism were not found21.
In the nervous system, the most common sign is the fine postural 
or action tremor, present in between 4 to 20% of cases22. The tremor is 
more frequent and associated with the use of caffeine, antidepressants 
and neuroleptics, and potentially alleviated by concomitant use of 
betablockers22. In regard to cognition, prolonged administration of 
lithium might produce discrete negative effects in learning, surveil-
lance, alert and in short-term memory23,24. Patients also might report 
mental and psychomotor slowing after its use25. Generally, in clinical 
practice, the negative effects on cognition are commonly observed in 
memory, vigilance and reaction time23. In a placebo-controlled study 
involving functional magnetic resonance lithium has been shown 
to produce small but significant reduction in brain signals during 
oxygen-dependent cognitive tasks26. Exceptionally, electroencepha-
lographic abnormalities, including non-convulsive status epilepticus, 
cerebellar changes and extrapyramidal signs may be present9.  
Thyroid and parathyroid disorders
Thyroid dysfunction has been described during lithium therapy, 
especially among females27-29. It is currently recognized that the 
treatment can inhibit the production of thyroid hormones and in-
duce clinical signs of hypothyroidism or hyperthyroidism, and even 
goiter. Lithium is concentrated inside the thyroid gland and has four 
potentially negative effects: inhibition of iodine uptake, inhibition 
of iodotyrosine coupling, alteration in thyroglobulin structure, and 
inhibition of thyroxine secretion30,31. The change in thyroid stimulat-
ing hormone or thyrotropin (TSH) is commonly common observed 
effect9. Lithium probably acts on the hypothalamus-pituitary axis 
resulting in an over-response of TSH release to thyrotropin-releasing 
hormone, as found in over 50% of patients in a previous study32. Both 
clinical and subclinical hypothyroidism showed a higher prevalence 
among lithium users33. The prevalence of clinical hypothyroidism 
was between 8 and 19% among users of lithium compared with 0.5 
to 1% in the general population33. Subclinical hypothyroidism pre-
sented a higher prevalence of 23% among lithium users compared 
to 10.3% from non-users33. In a study with 20 years of follow-up the 
incidence of hypothyroidism was 25/1000-year survivors34. A recent 
meta-analysis observed a six-fold increase of clinical hypothyroidism 
among patients receiving lithium therapy11.
There is a possible influence involving genetic, gender and 
clinical profile on hypothyroidism and lithium. In a prospective 
study, patients using lithium whose first-degree relatives had hy-
pothyroidism presented the disease faster (3.7 versus 8.6 years)35. 
From a large retrospective study, female patients presented a 10% 
increase in prevalence of hypothyroidism when compared to men 
(14% versus 4.5%)36. A prospective randomized study suggested that 
presence of hypothyroidism is associated with a lower response to 
the use of lithium37.
The incidence of thyroid goiter was present in 51% of 150 outpa-
tients evaluated in a clinical observational study38. In this study, 19% 
of subjects had subclinical hypothyroidism and 53% were positive 
for the presence of anti-thyroid antibodies, despite the absence of 
clinical cases of hypothyroidism, and positively correlated with age 
Table 1. Most prevalent organ-damage related to lithium treatment
Target organ/clinical status Organic lesion
Kidneys Mild tubular dysfunction, diabetes 
insipidus, nephrotic syndrome, 
glomerular impairment




Skin Acne, folliculitis, maculopapular 
eruptions, Psoriasis, alopecia 
Pregnancy Teratogenecity (Ebstein’s anomaly)
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and time of lithium treatment. The decline in thyroid function may 
be associated with the presence or not of anti-thyroperoxidase32.
It is recommended that thyroid function be assessed by labora-
tory tests before the start, after 3 months and every 6 to 12 months 
during lithium therapy29. If the TSH is between 5 and 10 mU/L, 
serum levels should be measured between 1 and 3 months. In case 
of levels above 10 mU/L, it is recommended the introduction of 
levothyroxine independent of the presence of symptoms, intend-
ing to continue treatment with lithium33. Whether treatment of 
hypothyroidism in patients given lithium should follow this line of 
recommendation is unclear.
Although less prevalent, the hyperthyroidism can also occur dur-
ing lithium treatment39. It was suggested that this dysfunction could 
be caused by an induction of an autoimmune thyroiditis or simply 
by exacerbation of a silent thyroiditis40. In a retrospective study of 
patients with hyperthyroidism, lithium exposure was associated with 
a 4.7-fold higher risk for developing silent thyroiditis40.
Long-term lithium treatment also appears to be associated with 
the presence of hyperparathyroidism and hypercalcemia41. Even with 
normal or low levels of phosphate, 10-42% of patients develop some 
degree of serum hypercalcemia, and 29% are associated with elevated 
parathyroid hormone (PTH)9. The mechanism although uncertain, 
is probably due to the inactivation of the calcium-sensing receptor 
and the interference with intracellular second messenger signaling, 
leading to a primary increased release of PTH, with secondary raise 
of serum calcium42. In a retrospective study, total serum calcium was 
found to be higher than the reference value in 6% of patients; ionized 
calcium was higher in 25% and serum PTH in 23%43. 
In an epidemiological study, patients treated with lithium for 
more than 15 years presented 3 to 6 times more hypercalcemia 
compared with the general population44. In a prospective study, 
patients who had never previously used lithium had elevated PTH 
and increased calcium reabsorption along with reduced excretion of 
calcium, unlike that commonly observed with primary hyperpara-
thyroidism45. Multiple case reports associated lithium use and hyper-
parathyroidism with single or multiple adenomas of the parathyroid 
glands42. A previous study observed that total calcium levels were 
significantly higher in the lithium-treated group compared to patients 
who were treated with other psychotropic agents35. Symptoms of 
hypercalcemia require suspension of lithium therapy immediately.
Current guidelines for bipolar disorder do not specify direct rec-
ommendations regarding serum monitoring of calcium and PTH46. 
Baseline blood tests before lithium prescription should include TSH, 
free tiroxine, PTH and calcium, and should be monitored every year 
or more frequently if any clinical suspicious of one of these disorders.
Renal impairment
The tubular and glomerular dysfunction among lithium users is 
reflected by loss of renal filtration capacity, which culminates in mild 
to severe impairment, and by functional loss with chronic kidney dis-
ease47. About 50% of patients taking lithium have decreased urinary 
concentration47. The mechanism involves four associated actions of 
lithium on the kidney in animal models: interference with the ability 
to generate cyclic adenosine monophosphate (AMP) in response to 
stimulation of antidiuretic hormone by the cortical portion of the 
collecting duct cells47; inhibition of adenosines triphosphatases48; 
suppression (downregulation) of the synthesis of aquaporins49; and 
interference with the production of prostaglandins50. The clinical 
result is the consequent thirst with polyuria reported by patients. 
Long-term studies reported approximately a 15% incidence of ir-
reversible decrease in the urinary concentrating ability of lithium 
users51,52. This effect can be more frequently found with lithium 
administered twice daily as compared with a single administration 
of an extended release formulation53,54. A study using other mark-
ers of kidney damage, such as β2-microglobulin (associated with 
proximal tubular injury) and glucosaminoglycan (component of the 
glomerular basement membrane) in 107 lithium users between 1 and 
15 years with bipolar disorder were compared with 29 controls with 
other psychiatric disorders55. The 24-hour urine volume and mark-
ers used in this study were high, while the osmolality was decreased 
in the group using lithium. The excretion of β2-microglobulin was 
significantly higher in patients with polyuria as well as in those with 
greatest impairment of urinary concentrating ability. The duration 
of lithium treatment was not correlated with the change in urinary 
concentrating ability. 
Tubular dysfunction may be more complex, represented by diabe-
tes insipidus, defined by a 24 hours urine output above 3 liters with a 
hypotonic characteristic (urinary osmolality ratio by plasma smaller 
than 1)9,47. Normally, this change is usually reversible by treatment 
(duration of lithium treatment about six years), but turns into an ir-
reversible damage after a long period of prescription (around 15 years 
or more). There are reports of a 27% incidence of diabetes insipidus 
in a short period of follow-up (4 months), significantly associated 
with the combined use of serotonergic antidepressants56. In a previous 
study, patients with bipolar disorder were evaluated for both renal 
and urinary concentrating ability dysfunction, being divided into 
three groups: 10 with no previous use of lithium, 10 with the use of 
short-term and 10 with long-term usage57. The creatinine clearance 
in patients with long-term regimen was significantly lower than that 
of the other two groups. After 8 hours of water deprivation and also 
after injection of desmopressin, there was no difference between 
groups in terms of urinary osmolality. However, when each patient 
was assessed individually in terms of their ability to concentrate 
kidney, there was partial diabetes insipidus in four patients in the 
long term and in two patients in short-term treatment. 
In this context, tubular dysfunction can occur during the initial 
treatment with lithium, can be independent of serum lithium levels, 
and even start with diabetes insipidus. However, the detection of early 
signs of tubular impairment from simple urinary analysis exam (e.g. 
altered urinary density) can provide a fast and easy way to handle 
with this possible adverse effect and avoid an irreversible lesion or a 
severe dysfunction such as diabetes insipidus.
The glomerular involvement is the most important organic 
adverse event related to lithium treatment. This dysfunction and its 
magnitude remains much more controversial in terms of prevalence 
among lithium users if we evaluate the evidence presented in most 
clinical studies, especially because there are a few well-designed 
studies such as long-term randomized and placebo-controlled10,11,47. 
A review of 14 studies that were published before 1987 estimated a 
15% prevalence for the reduction of glomerular filtration rate (GFR) 
(Button et al., 1987). Several studies between the 1980s and 1990s 
showed no significant change in GFR or just a slight functional de-
terioration with the use of lithium in the long-term follow-up43,58-63. 
However, five more recent studies reported that between 21 and 
55% of patients treated with lithium presented a GFR of less than 
60 ml/min/1.73 m2, corresponding to the cutoff for the third stage 
of renal disease64-69. A recent systematic review selected 23 studies 
that investigated the effect of the use of lithium on renal function, 
dividing them into three categories: cross-sectional case-control 
studies, pre and post-lithium treatment studies, and observational 
long-term studies10. In all three categories, increased creatinine was 
observed in favor of lithium users, being significant and very mild 
only in the first and third category10. However, Bendz et al.70 in an 
observational study reported a 1.2% prevalence of renal failure and 
a 2.5 times higher risk for dialysis among lithium users, resulting 
in a 6 fold greater risk for the disease than the general population. 
This study also noted that even with the interruption of the drug, 
creatinine level continued to increase if its previous level was above 
2.5 mg/dL when lithium was withdrawn70. In another epidemiological 
study with patients in dialysis across France, lithium was associated 
as a cause of renal failure in 2 among 1,000 subjects51.
In a transversal study with 13 long-term lithium users (mean us-
age: 10 years; mean blood levels: 0.66 mmol/L) and 13 controls were 
evaluated during the fifth and ninth week after lithium withdrawn44. 
Although there was no significant difference in GFR between the 
groups, there was an improvement in GFR among lithium users after 
the discontinuation. The maximum urinary concentrating ability 
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did not show any improvement after drug withdrawn, remaining 
lower in the group of lithium users44. In a retrospective study of this 
cohort after 8-12 years of follow-up, it was observed that both the 
urinary concentrating ability and GFR were not lower when com-
pared with those who died or who discontinued lithium65. Of this 
sample, one patient died attributed to severe renal impairment due 
to lithium. Urinary concentration ability and GFR were reevaluated 
in the remaining of this sample and were significantly declined when 
compared to baseline measures.
The exact time to develop glomerular dysfunction is not fully 
understood. In a retrospective study, 21% of the sample under lithium 
developed some degree of renal impairment66. Both the duration of 
treatment as well as the blood levels did not influence the develop-
ment of renal failure. In a prospective study, renal function was as-
sessed at the end of 11.5 years of follow-up71. Lithium users presented 
a lower GFR compared to controls, however the correlation between 
lithium exposure time and loss of renal function was not significant. 
Taking all this evidence into account, lithium can be associated 
with a possible glomerular dysfunction usually after long-term treat-
ment. However, end-stage renal impairment is not a common event. 
Monitoring renal function seems to be the best approach to avoid and 
manage this kind of adverse event, especially in patients with high risk 
of renal dysfunction such as those with hypertension and diabetes. 
Pregnancy and teratogenic risk
Although there is evidence that lithium may be teratogenic, they are 
not solid. Six case-control studies (n = 264) evaluated the associa-
tion of Ebstein’s anomaly and use of lithium, finding no significant 
difference in incidence when comparing women exposed and not 
exposed to lithium72. In addition, a major study comparing 10,698 
neonates with congenital abnormality 21,546 healthy neonates found 
no evidence of association of lithium with congenital anomalies73. The 
number of newborns exposed to lithium was small, both in affected 
cases (6 in 10,698) and in healthy controls (5 in 21,546 subjects).
Although one cannot rule out that lithium has a teratogenic 
potential, the current trend in the literature is to say that the risk has 
been overestimated at least. Therefore, one should avoid the use of 
lithium in the first trimester of pregnancy, but taking into account 
that the risk of teratogenesis may exist, but the prevalence is not as 
high as previously estimated.
If there is discovery of pregnancy in patients taking lithium and 
choose to discontinue the drug, discontinuation can be done gradu-
ally in 2-4 weeks as abrupt withdrawal is associated with increased 
risk of relapse74. It is recommended reintroducing lithium quickly 
after the baby’s birth, as the postpartum period increases the risk 
of relapse75.
Additional laboratorial and imaging findings
Some laboratorial findings can be early observed in patients with 
lithium, corresponding to biological effects of the drug even at 
low serum levels. Potential relevant changes in renal, thyroid and 
parathyroid function were addressed earlier in this review. It is quite 
commonly observed an increase in the leukocyte count secondary 
to a 1.5 times the upper limit of the neutrophil count in the com-
plete blood work of a patient using lithium76. Changes in glucose 
metabolism has been described, including the development of dia-
betes mellitus77,78. Most controlled studies have indirectly associated 
lithium with glucose intolerance or even diabetes, being this effect 
attributed to the weight gain secondary to the medication use77,79. 
Lithium may reduce the serum prolactin levels, unlike most other 
psychotropics80,81. Hypermagnesemia is also often associated with 
the use of lithium, reaching 30% of patients41.
Nonspecific changes of ventricular repolarization on the elec-
trocardiogram, without clinical symptoms, were described with 
the concomitant use of lithium, totaling 13 to 100% of patients, 
depending on the study74. Epileptic activity can be observed during 
an electroencephalogram without clinical manifestations82. This 
non-convulsive epilepsy is usually associated with a higher blood 
levels, although it can be seen at normal serum concentrations and 
at overt seizures83,84. 
In lithium users, there are also structural changes in the kidneys 
in addition to functional changes already described. Pathological 
findings in subjects treated with lithium show chronic tubulointer-
stitial nephropathy including tubular atrophy and interstitial fibrosis 
interspersed with tubular dilations and cysts85,86. The microcystic 
formations, usually multiple, are seen between 33 and 62.5% of 
patients on MRI scans, both in the cortex and in the medulla, espe-
cially in regions with extensive atrophy and fibrosis85,86. Normally, 
the involvement is bilateral and sparse, not exceeding 1-2mm in 
diameter85,86. Cysts may exceed 3mm and did not correlate with the 
presence of renal dysfunction87.
Pharmacological interaction
The main drugs that can interfere with the plasma concentrations of 
lithium, increasing them, are alprazolam88, thiazide diuretics, ACE 
inhibitors89 and anti-inflammatory non-steroidal drugs. Therefore, it 
is safe to reduce the amount of lithium in 40-50% before prescribing 
a diuretic, for example. Amiloride is preferable to others diuretics as 
it less likely affects lithium levels, given its ability to block lithium 
uptake at the epithelial sodium channel90. Drugs that lower lithium 
concentrations by increasing the clearance are theophylline, acet-
azolamide, mannitol and caffeine38.
It is important to note that the use of propranolol can decrease 
lithium clearance77. Caution is required when administering calcium 
channel antagonists and angiotensin II antagonists with lithium, 
since several reports on poisoning in combination of lithium have 
been described78,79. The use of xanthines (theophylline, caffeine) 
may increase 20-25% of the current lithium blood levels. The use of 
NSAIDs (excluding acetylsalicylic acid) requires reduction of about 
20% of the administered dose of lithium83.
The safety of the use of lithium in patients receiving electrocon-
vulsive therapy (ECT) is controversial. There are two studies that 
found an incidence of 5-10% of delirium in patients who were using 
electroconvulsive therapy in combination with lithium82,91. Therefore, 
it is prudent to suspend or lower the dose of lithium among patients 
elected to electroconvulsive therapy.
Conclusions
Lithium is a standard treatment for bipolar disorder, also indicated in 
association with antidepressants for unipolar depression. Short-term 
lithium use has only mild side effects and that the most severe side ef-
fects (on target organs) are not common and can be prevented through 
periodical monitoring in subjects requiring chronic treatment.
The authors of the present manuscript report no conflict of inter-
est in the conduction of this study.
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